Literature DB >> 20944091

Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.

Kristina Kirschner1, David W Melton.   

Abstract

In this review, we focus on the discrepant roles of the DNA repair complex ERCC1/XPF in the prevention of cancer and in the resistance of cancer to chemotherapy. ERCC1/XPF is essential for nucleotide excision repair (NER) incising DNA 5' to the lesion. NER deficiency results in the skin cancer-prone inherited disease xeroderma pigmentosum (XP). The ERCC1/XPF complex is also involved in recombination, double strand break (DSB) and interstrand crosslink (ICL) repair cutting DNA overhangs around a lesion. In telomere maintenance ERCC1/XPF degrades 3' G-rich overhangs. In some types of cancer, high levels of ERCC1/XPF mRNA and protein correlate with poor overall survival and resistance to platinum-based chemotherapeutic treatments. Therefore, the ERCC1/XPF complex makes an attractive target for prediction of outcome for treatment in cancer patients as well as a novel drug target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944091

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  55 in total

Review 1.  Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Authors:  Spyridon P Basourakos; Likun Li; Ana M Aparicio; Paul G Corn; Jeri Kim; Timothy C Thompson
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

2.  γ-secretase inhibition combined with cisplatin enhances apoptosis of nasopharyngeal carcinoma cells.

Authors:  Jun-Xu Zhou; Ji-Bo Han; Shi-Ming Chen; Yu Xu; Yong-Gang Kong; Bo-Kui Xiao; Ze-Zhang Tao
Journal:  Exp Ther Med       Date:  2011-12-06       Impact factor: 2.447

3.  High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer.

Authors:  Dong Hyun Kim; Hyunjoo Lee; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn; Kyungeun Kim; Sung-Im Do
Journal:  Oncol Lett       Date:  2017-08-09       Impact factor: 2.967

4.  A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.

Authors:  Jian Cheng; Minwen Ha; Yadi Wang; Jing Sun; Junchen Chen; Yue Wang; Chunyan Tong
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-20       Impact factor: 4.553

5.  PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Authors:  Haiying Cheng; Zhenfeng Zhang; Alain Borczuk; Charles A Powell; Adayabalam S Balajee; Howard B Lieberman; Balazs Halmos
Journal:  Carcinogenesis       Date:  2012-12-28       Impact factor: 4.944

6.  ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.

Authors:  Sebastian Prochnow; W Wilczak; V Bosch; T S Clauditz; A Muenscher
Journal:  Clin Oral Investig       Date:  2018-11-29       Impact factor: 3.573

7.  Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.

Authors:  Junkai Li; Xiaoyan Zuo; Xiaoyan Lv; Fanjun Kong; Wen Xu; Shujuan Yang
Journal:  Tumour Biol       Date:  2014-05-04

8.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31

Review 9.  Combating Drug Resistance in Colorectal Cancer Using Herbal Medicines.

Authors:  Ga-Young Lee; Jin-Seok Lee; Chang-Gue Son; Nam-Hun Lee
Journal:  Chin J Integr Med       Date:  2020-08-01       Impact factor: 1.978

10.  Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells.

Authors:  Lin Lv; Hai-Guang Liu; Si-Yang Dong; Fan Yang; Qing-Xuan Wang; Gui-Long Guo; Yi-Fei Pan; Xiao-Hua Zhang
Journal:  Tumour Biol       Date:  2016-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.